Sanofi (SAN.PA) Stock Price

Sanofi Price

🇫🇷Euronext·CLOSED
76.39EUR
Market closed
Today +/-
Today %

Sanofi (SAN.PA) Stock | ISIN FR0000120578 | WKN 920657. The current Sanofi stock price is 76.39 EUR (2026). Revenue is 47.94 B EUR. Net income is 10.32 B EUR. The P/E ratio is 9.04. Market capitalization is 93.23 B EUR. Sanofi operates in the Health sector.

Sanofi stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sanofi over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sanofi stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sanofi's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sanofi Stock Price History
DateSanofi Price
Access this data via the Eulerpool API
Get Free API Key

Sanofi Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
29.49 B EUR
5.73 B EUR
4.01 B EUR
Jan 1, 2007
29.21 B EUR
6.11 B EUR
5.26 B EUR
Jan 1, 2008
28.82 B EUR
6.46 B EUR
3.85 B EUR
Jan 1, 2009
31.23 B EUR
7.89 B EUR
5.27 B EUR
Jan 1, 2010
34.04 B EUR
8.49 B EUR
5.47 B EUR
Jan 1, 2011
35.06 B EUR
7.5 B EUR
5.69 B EUR
Jan 1, 2012
35.96 B EUR
7.88 B EUR
4.89 B EUR
Jan 1, 2013
31.29 B EUR
6.36 B EUR
3.72 B EUR
Jan 1, 2014
32 B EUR
6.74 B EUR
4.39 B EUR
Jan 1, 2015
34.86 B EUR
7.13 B EUR
4.29 B EUR
Jan 1, 2016
34.7 B EUR
7.53 B EUR
4.71 B EUR
Jan 1, 2017
36.22 B EUR
7.2 B EUR
8.42 B EUR
Jan 1, 2018
35.68 B EUR
6.26 B EUR
4.31 B EUR
Jan 1, 2019
37.63 B EUR
6.78 B EUR
2.75 B EUR
Jan 1, 2020
37.37 B EUR
7.38 B EUR
12.29 B EUR

Sanofi Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 8:37 PM
 
REVENUE (M EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
DIV. (EUR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sanofi generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sanofi retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sanofi's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sanofi has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sanofi's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sanofi stock margins

The Sanofi margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sanofi. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sanofi.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
74.27 %
19.43 %
13.58 %
Jan 1, 2007
74.08 %
20.91 %
18.02 %
Jan 1, 2008
74.54 %
22.41 %
13.36 %
Jan 1, 2009
74.04 %
25.25 %
16.86 %
Jan 1, 2010
72.39 %
24.94 %
16.06 %
Jan 1, 2011
68.9 %
21.39 %
16.24 %
Jan 1, 2012
69.14 %
21.92 %
13.6 %
Jan 1, 2013
67.08 %
20.32 %
11.88 %
Jan 1, 2014
68.03 %
21.06 %
13.72 %
Jan 1, 2015
68.68 %
20.46 %
12.3 %
Jan 1, 2016
69.16 %
21.69 %
13.57 %
Jan 1, 2017
67.94 %
19.88 %
23.24 %
Jan 1, 2018
67.95 %
17.53 %
12.07 %
Jan 1, 2019
68.17 %
18.01 %
7.32 %
Jan 1, 2020
67.46 %
19.76 %
32.9 %

Sanofi Stock Revenue, EBIT, Earnings per Share

The Sanofi earnings per share therefore indicates how much revenue Sanofi has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
21.7 EUR
4.22 EUR
2.95 EUR
Jan 1, 2007
21.57 EUR
4.51 EUR
3.89 EUR
Jan 1, 2008
21.98 EUR
4.93 EUR
2.94 EUR
Jan 1, 2009
23.89 EUR
6.03 EUR
4.03 EUR
Jan 1, 2010
26.02 EUR
6.49 EUR
4.18 EUR
Jan 1, 2011
26.42 EUR
5.65 EUR
4.29 EUR
Jan 1, 2012
27.04 EUR
5.93 EUR
3.68 EUR
Jan 1, 2013
23.37 EUR
4.75 EUR
2.77 EUR
Jan 1, 2014
24.04 EUR
5.06 EUR
3.3 EUR
Jan 1, 2015
26.4 EUR
5.4 EUR
3.25 EUR
Jan 1, 2016
26.77 EUR
5.81 EUR
3.63 EUR
Jan 1, 2017
28.59 EUR
5.69 EUR
6.64 EUR
Jan 1, 2018
28.42 EUR
4.98 EUR
3.43 EUR
Jan 1, 2019
29.93 EUR
5.39 EUR
2.19 EUR
Jan 1, 2020
29.66 EUR
5.86 EUR
9.76 EUR

Sanofi business model & stock analysis

Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide.

Sanofi SWOT Analysis

Strengths

Sanofi SA has a strong global presence with operations in multiple countries, providing a broad customer base and diversification.

The company has a robust portfolio of products across various therapeutic areas, including pharmaceuticals, vaccines, and consumer healthcare.

Sanofi SA invests heavily in research and development, ensuring the continuous development of innovative drugs and treatments.

Weaknesses

Sanofi SA faces challenges in patent expirations and generic competition, impacting its market share and revenue.

The company has a high dependence on a few key products, posing a risk if any of those products face regulatory issues or fail to meet market expectations.

Sanofi SA's operations in emerging markets are vulnerable to regulatory and political risks, affecting its growth potential in those regions.

Opportunities

Increasing healthcare spending globally presents opportunities for Sanofi SA to expand its market presence and reach a larger customer base.

The growing demand for personalized medicine and advancements in technology offer possibilities for Sanofi SA to develop targeted therapies and innovative treatment approaches.

Strategic collaborations and partnerships can help Sanofi SA to access new markets, leverage expertise, and drive business growth.

Threats

Sanofi SA faces intense competition from other pharmaceutical companies, leading to price pressures and potential loss of market share.

Regulatory complexities and increasing scrutiny on drug pricing and access may impact Sanofi SA's profitability and market position.

Economic uncertainties and geopolitical factors can adversely affect Sanofi SA's global operations and financial performance.

Sanofi Eulerpool Fair Value

Sanofi historical P/E ratio, EBIT multiple, and P/S ratio

Sanofi annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sanofi shares outstanding

The number of shares was Sanofi in 2025 — This indicates how many shares 1.22 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
1.36 B base_Shares
Jan 1, 2007
1.35 B base_Shares
Jan 1, 2008
1.31 B base_Shares
Jan 1, 2009
1.31 B base_Shares
Jan 1, 2010
1.31 B base_Shares
Jan 1, 2011
1.33 B base_Shares
Jan 1, 2012
1.33 B base_Shares
Jan 1, 2013
1.34 B base_Shares
Jan 1, 2014
1.33 B base_Shares
Jan 1, 2015
1.32 B base_Shares
Jan 1, 2016
1.3 B base_Shares
Jan 1, 2017
1.27 B base_Shares
Jan 1, 2018
1.26 B base_Shares
Jan 1, 2019
1.26 B base_Shares
Jan 1, 2020
1.26 B base_Shares

Sanofi Dividend History

27 years of dividend payments · 20 consecutive increases

YearAnnual DividendYoY ChangePayments
20264.12EURYTD—1×
May 5, 20264.12EUR↑ 5.1%1/1
20253.92EUR↑ 4.3%1×
May 12, 20253.92EUR↑ 4.3%1/1
20243.76EUR↑ 5.6%1×
20233.56EUR↑ 7.5%1×
20223.31EUR↑ 3.5%1×
20213.2EUR↑ 1.6%1×
20203.15EUR↑ 2.6%1×
20193.07EUR↑ 1.3%1×
20183.03EUR↑ 2.4%1×
20172.96EUR↑ 1.0%1×

Sanofi dividend history and estimates

In 2025, Sanofi paid a dividend amounting to 3.92 EUR. Dividend means that Sanofi distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
1.52 EUR
0 EUR
Jan 1, 2007
1.75 EUR
0 EUR
Jan 1, 2008
2.07 EUR
0 EUR
Jan 1, 2009
2.2 EUR
0 EUR
Jan 1, 2010
2.4 EUR
0 EUR
Jan 1, 2011
2.5 EUR
0 EUR
Jan 1, 2012
2.65 EUR
0 EUR
Jan 1, 2013
2.77 EUR
0 EUR
Jan 1, 2014
2.8 EUR
0 EUR
Jan 1, 2015
2.85 EUR
0 EUR
Jan 1, 2016
2.93 EUR
0 EUR
Jan 1, 2017
2.96 EUR
0 EUR
Jan 1, 2018
3.03 EUR
0 EUR
Jan 1, 2019
3.07 EUR
0 EUR
Jan 1, 2020
3.15 EUR
0 EUR

Sanofi dividend payout ratio

In 2025, Sanofi had a payout ratio of 51.02%. The payout ratio indicates the percentage of the company's profits that Sanofi distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
51.53 %
Jan 1, 2007
45.1 %
Jan 1, 2008
70.65 %
Jan 1, 2009
54.59 %
Jan 1, 2010
57.42 %
Jan 1, 2011
58.28 %
Jan 1, 2012
72.01 %
Jan 1, 2013
100 %
Jan 1, 2014
85.11 %
Jan 1, 2015
87.96 %
Jan 1, 2016
80.72 %
Jan 1, 2017
44.58 %
Jan 1, 2018
88.08 %
Jan 1, 2019
140.18 %
Jan 1, 2020
32.27 %
Price targets and forecasts for Sanofi are not yet available.

Sanofi Earnings Estimates

Sanofi Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
10/28/20222.7EUR12.25 BEUR2022 Q3
7/28/20221.66EUR9.9 BEUR2022 Q2
4/28/20221.79EUR9.54 BEUR2022 Q1
2/4/20221.35EUR10.41 BEUR2021 Q4
10/28/20212.01EUR10.44 BEUR2021 Q3
7/29/20211.32EUR8.66 BEUR2021 Q2
4/28/20211.4EUR8.76 BEUR2021 Q1
2/5/20211.17EUR9.73 BEUR2020 Q4
10/29/20201.82EUR9.87 BEUR2020 Q3
7/29/20201.25EUR8.61 BEUR2020 Q2

EESG©

Eulerpool ESG Scorecard© for the Sanofi stock

85/100
90
Environment
88
Social
75
Governance
E

Environment

20
Scope 1 - Direct Emissions298,485
Scope 2 - Indirect emissions from purchased energy318,252
Scope 3 - Indirect emissions within the value chain3,822,627
Total CO₂ emissions616,737
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49.6
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sanofi shareholder structure

% Name
7.2657%
L'Oreal SA
L'Oreal SA
7.20811%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.24096%
Capital Research Global Investors
Capital Research Global Investors
3.09613%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.63829%
Sanofi SA Employees
Sanofi SA Employees
1.85862%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.47236%
Dodge & Cox
Dodge & Cox
1.20616%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
1.19834%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
0.98394%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Sanofi Executives and Management Board

PH

Mr. Paul Hudson

(57)

Chief Executive Officer, Executive Director, Member of the Executive Committee · since 2019

Compensation3.79 M EUR
FO

Mr. Frederic Oudea

(61)

Independent Chairman of the Board

Compensation884,836 EUR
CF

Ms. Carole Ferrand

(54)

Independent Director

Compensation197,750 EUR
PK

Mr. Patrick Kron

(71)

Independent Director

Compensation195,000 EUR
AY

Dr. Antoine Yver

(67)

Independent Director

Compensation184,000 EUR

Sanofi Supply Chain

Frequently asked questions about Sanofi

The business model of Sanofi SA, a renowned pharmaceutical company, revolves around the research, development, manufacturing, and distribution of a wide range of healthcare products. Sanofi SA is committed to providing innovative solutions, convenient access to medication, and improving global health outcomes. Its diversified portfolio includes prescription drugs, vaccines, over-the-counter medicines, and health-related products across various therapeutic areas. The company consistently invests in cutting-edge research, collaborations, and mergers to advance healthcare advancements. Sanofi SA's focus on patient-centric initiatives, strategic partnerships, and global presence allows it to meet the evolving healthcare needs and make a positive impact on the lives of millions worldwide.

All fundamentals and in-depth analysis of Sanofi

Our stock analysis for Sanofi Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanofi Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sanofi Stock
Sanofi Revenue→
Sanofi Stock
Sanofi Net Income→
Sanofi Stock
Sanofi P/E→
Sanofi Stock
Sanofi P/S→
Sanofi Stock
Sanofi EBIT→
Sanofi Stock
Sanofi Dividend→
Sanofi Stock
Sanofi Directors Dealings→
Sanofi Stock
Sanofi Stocks→
Sanofi Stock
Sanofi Market capitalization→
Sanofi Stock
Sanofi Debt→
Sanofi Stock
Sanofi Liabilities→
Sanofi Stock
Sanofi Equity→
Sanofi Stock
Sanofi AAQS→
Sanofi Stock
Sanofi Employees→
Sanofi Stock
Sanofi ROE→
Sanofi Stock
Sanofi ROA→
Sanofi Stock
Sanofi ROCE→